IL15 and renal cell carcinoma: While this design has demonstrated potent antitumor activity against human RCC in both in vitro and in vivo models,1,19 IL-15 overexpression may raise potential safety concerns, as suggested by observations from recent phase I clinical trials involving IL-15–augmented CAR-T cells in patients with hepatocellular carcinoma (HCC).20